355113-98-3
Chemical Structure
BMS 275183
- CAS. Nr.: 355113-98-3
- Formula:C43H59NO16
- Molecular Weight:845.93
IUPAC Name: (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4,4-dimethylpentanoyl)oxy)-4,11-dihydroxy-12b-((methoxycarbonyl)oxy)-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate
InChIKey: AHXICHPPXIGCBN-GPWPDEGDSA-N
SMILES: COC(O[C@]12[C@@]([C@]3([C@@H](O)C[C@@]1([H])OC2)C)([H])[C@@H]([C@]4(C(C)(C([C@@H](OC(C)=O)C3=O)=C(C)[C@@H](OC([C@H](O)[C@H](C(C)(C)C)NC(OC(C)(C)C)=O)=O)C4)C)O)OC(C5=CC=CC=C5)=O)=O
Biological Activity: BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS 275183 | BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
